Skip to main content
PMC home page
British Journal of Pharmacology logoLink to British Journal of Pharmacology
. 1995 Jan;114(2):405–413. doi: 10.1111/j.1476-5381.1995.tb13241.x

In vivo pharmacological characterization of the non-peptide endothelin receptor antagonist SB 209670.

S A Douglas 1, R M Edwards 1, J D Elliott 1, E H Ohlstein 1
PMCID: PMC1510235  PMID: 7881741

Abstract

1. The aim of the present study was to assess the ability of SB 209670, a high affinity non-peptide endothelin receptor antagonist (0.4 and 18 nM Kis at human cloned ETA and ETB receptors, respectively), to inhibit the haemodynamic actions of endothelin-1 in vivo. 2. Systemic administration of (+/-)-SB 209670, given either as a bolus i.v. injection or as a continuous i.v. infusion, did not alter basal haemodynamic parameters in the anaesthetized rat. 3. Infusion of (+/-)-SB 209670 (10 micrograms kg-1 min-1) selectively inhibited the depressor and carotid vasodilator response to exogenous endothelin-1: 100 micrograms kg-1 min-1 was required to inhibit significantly the biphasic haemodynamic actions of endothelin-1. The haemodynamic actions of angiotensin II and calcitonin gene-related peptide were unaltered by 100 micrograms kg-1 min-1 (+/-)-SB 209670. 4. Bolus i.v. administration of (+/-)-SB 209670 (1 mg kg-1) selectively inhibited the depressor and carotid vasodilator actions of endothelin-1: 10 mg kg-1 (+/-)-SB 209670 was required to inhibit the secondary vasoconstrictor actions of endothelin-1. 5. (+/-)-SB 209670 (10 mg kg-1) was also effective at antagonizing the pressor actions of endothelin-1 in the conscious rat for up to 3 h after intraduodenal administration thereby demonstrating that the antagonist was bioavailable upon enteric administration. This dose of (+/-)-SB 209670 did not alter basal haemodynamic parameters in the conscious rat.(ABSTRACT TRUNCATED AT 250 WORDS)

Full text

PDF
405

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bigaud M., Pelton J. T. Discrimination between ETA- and ETB-receptor-mediated effects of endothelin-1 and [Ala1,3,11,15]endothelin-1 by BQ-123 in the anaesthetized rat. Br J Pharmacol. 1992 Dec;107(4):912–918. doi: 10.1111/j.1476-5381.1992.tb13385.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Clozel M., Breu V., Burri K., Cassal J. M., Fischli W., Gray G. A., Hirth G., Löffler B. M., Müller M., Neidhart W. Pathophysiological role of endothelin revealed by the first orally active endothelin receptor antagonist. Nature. 1993 Oct 21;365(6448):759–761. doi: 10.1038/365759a0. [DOI] [PubMed] [Google Scholar]
  3. Clozel M., Breu V., Gray G. A., Löffler B. M. In vivo pharmacology of Ro 46-2005, the first synthetic nonpeptide endothelin receptor antagonist: implications for endothelin physiology. J Cardiovasc Pharmacol. 1993;22 (Suppl 8):S377–S379. doi: 10.1097/00005344-199322008-00099. [DOI] [PubMed] [Google Scholar]
  4. Cody W. L., Doherty A. M., He J. X., DePue P. L., Rapundalo S. T., Hingorani G. A., Major T. C., Panek R. L., Dudley D. T., Haleen S. J. Design of a functional hexapeptide antagonist of endothelin. J Med Chem. 1992 Aug 21;35(17):3301–3303. doi: 10.1021/jm00095a029. [DOI] [PubMed] [Google Scholar]
  5. Doherty A. M., Cody W. L., He J. X., DePue P. L., Cheng X. M., Welch K. M., Flynn M. A., Reynolds E. E., LaDouceur D. M., Davis L. S. In vitro and in vivo studies with a series of hexapeptide endothelin antagonists. J Cardiovasc Pharmacol. 1993;22 (Suppl 8):S98–102. doi: 10.1097/00005344-199322008-00027. [DOI] [PubMed] [Google Scholar]
  6. Douglas S. A., Elliott J. D., Ohlstein E. H. Regional vasodilation to endothelin-1 is mediated by a non-ETA receptor subtype in the anaesthetized rat: effect of BQ-123 on systemic haemodynamic responses. Eur J Pharmacol. 1992 Oct 20;221(2-3):315–324. doi: 10.1016/0014-2999(92)90718-j. [DOI] [PubMed] [Google Scholar]
  7. Douglas S. A., Gellai M., Ezekiel M., Ohlstein E. H. BQ-123, a selective endothelin subtype A-receptor antagonist, lowers blood pressure in different rat models of hypertension. J Hypertens. 1994 May;12(5):561–567. [PubMed] [Google Scholar]
  8. Douglas S. A., Hiley C. R. Endothelium-dependent mesenteric vasorelaxant effects and systemic actions of endothelin (16-21) and other endothelin-related peptides in the rat. Br J Pharmacol. 1991 Oct;104(2):311–320. doi: 10.1111/j.1476-5381.1991.tb12428.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Douglas S. A., Hiley C. R. Endothelium-dependent vascular activities of endothelin-like peptides in the isolated superior mesenteric arterial bed of the rat. Br J Pharmacol. 1990 Sep;101(1):81–88. doi: 10.1111/j.1476-5381.1990.tb12093.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Gardiner S. M., Compton A. M., Bennett T. Regional hemodynamic effects of endothelin-1 in conscious, unrestrained, Wistar rats. J Cardiovasc Pharmacol. 1989;13 (Suppl 5):S202–S204. doi: 10.1097/00005344-198900135-00057. [DOI] [PubMed] [Google Scholar]
  11. Gardiner S. M., Kemp P. A., March J. E., Bennett T., Davenport A. P., Edvinsson L. Effects of an ET1-receptor antagonist, FR139317, on regional haemodynamic responses to endothelin-1 and [Ala11,15]Ac-endothelin-1 (6-21) in conscious rats. Br J Pharmacol. 1994 Jun;112(2):477–486. doi: 10.1111/j.1476-5381.1994.tb13098.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Gardiner S. M., Kemp P. A., March J. E., Bennett T. Effects of bosentan (Ro 47-0203), an ETA-, ETB-receptor antagonist, on regional haemodynamic responses to endothelins in conscious rats. Br J Pharmacol. 1994 Jul;112(3):823–830. doi: 10.1111/j.1476-5381.1994.tb13153.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Harrison V. J., Randriantsoa A., Schoeffter P. Heterogeneity of endothelin-sarafotoxin receptors mediating contraction of pig coronary artery. Br J Pharmacol. 1992 Mar;105(3):511–513. doi: 10.1111/j.1476-5381.1992.tb09009.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Hiley C. R., Douglas S. A., Randall M. D. Pressor effects of endothelin-1 and some analogs in the perfused superior mesenteric arterial bed of the rat. J Cardiovasc Pharmacol. 1989;13 (Suppl 5):S197–S199. doi: 10.1097/00005344-198900135-00055. [DOI] [PubMed] [Google Scholar]
  15. Ihara M., Noguchi K., Saeki T., Fukuroda T., Tsuchida S., Kimura S., Fukami T., Ishikawa K., Nishikibe M., Yano M. Biological profiles of highly potent novel endothelin antagonists selective for the ETA receptor. Life Sci. 1992;50(4):247–255. doi: 10.1016/0024-3205(92)90331-i. [DOI] [PubMed] [Google Scholar]
  16. Le Monnier de Gouville A. C., Lippton H., Cohen G., Cavero I., Hyman A. Vasodilator activity of endothelin-1 and endothelin-3: rapid development of cross-tachyphylaxis and dependence on the rate of endothelin administration. J Pharmacol Exp Ther. 1990 Sep;254(3):1024–1028. [PubMed] [Google Scholar]
  17. Moreland S., McMullen D. M., Delaney C. L., Lee V. G., Hunt J. T. Venous smooth muscle contains vasoconstrictor ETB-like receptors. Biochem Biophys Res Commun. 1992 Apr 15;184(1):100–106. doi: 10.1016/0006-291x(92)91163-k. [DOI] [PubMed] [Google Scholar]
  18. Ohlstein E. H., Gellai M., Brooks D. P., Vickery L., Jugus J., Sulpizio A., Ruffolo R. R., Jr, Weinstock J., Edwards R. M. The antihypertensive effect of the angiotensin II receptor antagonist DuP 753 may not be due solely to angiotensin II receptor antagonism. J Pharmacol Exp Ther. 1992 Aug;262(2):595–601. [PubMed] [Google Scholar]
  19. Ohlstein E. H., Nambi P., Douglas S. A., Edwards R. M., Gellai M., Lago A., Leber J. D., Cousins R. D., Gao A., Frazee J. S. SB 209670, a rationally designed potent nonpeptide endothelin receptor antagonist. Proc Natl Acad Sci U S A. 1994 Aug 16;91(17):8052–8056. doi: 10.1073/pnas.91.17.8052. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Panek R. L., Major T. C., Hingorani G. P., Doherty A. M., Taylor D. G., Rapundalo S. T. Endothelin and structurally related analogs distinguish between endothelin receptor subtypes. Biochem Biophys Res Commun. 1992 Mar 16;183(2):566–571. doi: 10.1016/0006-291x(92)90519-q. [DOI] [PubMed] [Google Scholar]
  21. Spokes R. A., Ghatei M. A., Bloom S. R. Studies with endothelin-3 and endothelin-1 on rat blood pressure and isolated tissues: evidence for multiple endothelin receptor subtypes. J Cardiovasc Pharmacol. 1989;13 (Suppl 5):S191–S192. doi: 10.1097/00005344-198900135-00053. [DOI] [PubMed] [Google Scholar]
  22. Sumner M. J., Cannon T. R., Mundin J. W., White D. G., Watts I. S. Endothelin ETA and ETB receptors mediate vascular smooth muscle contraction. Br J Pharmacol. 1992 Nov;107(3):858–860. doi: 10.1111/j.1476-5381.1992.tb14537.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Warner T. D., Allcock G. H., Mickley E. J., Corder R., Vane J. R. Comparative studies with the endothelin receptor antagonists BQ-123 and PD 142893 indicate at least three endothelin receptors. J Cardiovasc Pharmacol. 1993;22 (Suppl 8):S117–S120. doi: 10.1097/00005344-199322008-00032. [DOI] [PubMed] [Google Scholar]
  24. de Nucci G., Thomas R., D'Orleans-Juste P., Antunes E., Walder C., Warner T. D., Vane J. R. Pressor effects of circulating endothelin are limited by its removal in the pulmonary circulation and by the release of prostacyclin and endothelium-derived relaxing factor. Proc Natl Acad Sci U S A. 1988 Dec;85(24):9797–9800. doi: 10.1073/pnas.85.24.9797. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from British Journal of Pharmacology are provided here courtesy of The British Pharmacological Society

RESOURCES